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Background: Cardiovascular magnetic resonance (CMR) derived native myocardial T1 is decreased in patients with Fabry
disease even before left ventricular hypertrophy (LVH) occurs and may be the first non-invasive measure of myocyte
sphingolipid storage. The relationship of native T1 lowering prior to hypertrophy and other candidate early phenotype
markers are unknown. Furthermore, the reproducibility of T1 mapping has never been assessed in Fabry disease.
Methods: Sixty-three patients, 34 (54%) female, mean age 48 ± 15 years with confirmed (genotyped) Fabry disease
underwent CMR, ECG and echocardiographic assessment. LVH was absent in 25 (40%) patients. Native T1 mapping was
performed with both Modified Look-Locker Inversion recovery (MOLLI) sequences and a shortened version (ShMOLLI) at
1.5 Tesla. Twenty-one patients underwent a second scan within 24 hours to assess inter-study reproducibility. Results were
compared with 63 healthy age and gender-matched volunteers.
Results: Mean native T1 in Fabry disease (LVH positive), (LVH negative) and healthy volunteers was 853 ± 50 ms, 904 ±
46 ms and 968 ± 32 ms (for all p < 0.0001) by ShMOLLI sequences. Native T1 showed high inter-study, intra-observer and
inter-observer agreement with intra-class correlation coefficients (ICC) of 0.99, 0.98, 0.97 (ShMOLLI) and 0.98, 0.98, 0.98
(MOLLI). In Fabry disease LVH negative individuals, low native T1 was associated with reduced echocardiographic-based
global longitudinal speckle tracking strain (−18 ± 2% vs −22 ± 2%, p = 0.001) and early diastolic function impairment
(E/E’ = 7 [6–8] vs 5 [5–6], p = 0.028).
Conclusion: Native T1 mapping in Fabry disease is a reproducible technique. T1 reduction prior to the onset of LVH is
associated with early diastolic and systolic changes measured by echocardiography.
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Fabry disease is a rare but treatable X-linked disorder of
lysosomal metabolism caused by reduced or absent ac-
tivity of the alpha galactosidase enzyme, resulting in lyso-
somal sphingolipid accumulation in a number of different
organs. Since the advent of renal replacement therapy, the* Correspondence: j.moon@ucl.ac.uk
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Left ventricular hypertrophy (LVH), valve thickening,
myocardial scarring, progression to heart failure and sud-
den arrhythmic death may occur [1,2]. Fabry disease pa-
tients can be treated with enzyme replacement therapy
(ERT) [3]. A number of major challenges in the clinical
care of patients with potential Fabry disease remain, such
as: (i) the differential diagnosis of Fabry disease-related
LVH vs other causes of LVH; (ii) the detection of early car-
diac involvement in genetically diagnosed Fabry disease
patients (particularly in female heterozygotes); (iii) Timing. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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myocardial storage (hypertrophy, fibrosis, cell loss) is not
understood, but there is suggestion that therapy should be
started early before changes are permanent [4]. However,
treatment is sufficiently expensive that early therapy would
have societal cost implications [5-7]. New, non-invasive
markers of myocardial storage are therefore needed.
Recent advances in cardiovascular magnetic resonance
(CMR) allow measurement of native myocardial T1 using
a single, short breath-hold mapping sequence [8]. Native
T1 is known to be higher in fibrosis, edema and amyloid,
and lower in iron overload and focal fat infiltration [9-11].
In Fabry disease with LVH, both our group and another
have shown that native myocardial T1 is substantially
lower compared to other LVH aetiologies [12,13] and
around half of Fabry disease patients without LVH have
T1 lowering when compared to healthy volunteers [13].
The known lowering of T1 by fat and the early spectro-
scopic results suggest that native T1 may be directly meas-
uring myocardial storage in Fabry disease [12]. Native T1
mapping therefore has the potential role in clinical evalu-
ation (prognosis, differential diagnosis and early detection)
and management (timing of therapy and follow up) of
Fabry disease patients and as a tool to help in understand-
ing the biology of myocardial storage. However, several
questions regarding the use of T1 mapping in Fabry disease
remain, particularly its reproducibility and whether low na-
tive T1 in LVH negative patients is a real marker of early
disease with potential functional consequences.
In this study we investigated the reproducibility of na-
tive T1 assessment in Fabry disease and the relationship
of native T1 in Fabry disease patients with no LVH, look-
ing for functional (electrocardiographic, mechanical) cor-
relations of T1 reduction.
Methods
This research received approval from the local research
ethics committee and all participants provided written
informed consent. Patients were prospectively recruited
from the department of inherited cardiovascular disease
at The Heart Hospital, London, UK. All patients had a
genetically confirmed diagnosis of Fabry disease. This
population was compared with gender and age matched
cohorts of healthy volunteers: one for the whole popula-
tion of Fabry disease, one for the male cohort and one
for the female cohort, selected from a pool of 63 healthy
volunteers, as previously described [13].
CMR was performed on a 1.5 T magnet (Avanto, Sie-
mens Medical Solutions). Left ventricular volume, mass
and ejection fraction were calculated from steady state
free precession cine imaging using a thresholding method.
LVH was defined as an elevated indexed left ventricular
mass based on body surface area (BSA) normalized cut-off
values and stratified for age and gender (Table 1) [14].Native T1 measurement was performed using a Short-
ened Modified Look Locker Inversion recovery (ShMOLLI)
sequence. In the reproducibility group a second sequence,
Modified Look Locker Inversion recovery (MOLLI – sam-
pling scheme 5 s(3 s)3 s with motion correction) was also
performed and the patient removed from the scanner, to
be re-scanned later in the day; in this group, ShMOLLI
and MOLLI T1 assessment were then repeated. The mini-
mum and maximum time between scan 1 and 2 was 8 to
40 minutes. A shim box was placed tightly over the heart
as recommended [15]. Optimal gating and breath-holding
were ensured and raw images and error maps were exam-
ined for potential image artefacts during scanning, to allow
an immediate repeat of suboptimal measurements [8]. Fol-
lowing the second T1 assessment, standard late gadolinium
enhancement (LGE) imaging was performed on all pa-
tients. In patients not undergoing reproducibility, LGE was
performed at the end of the first and only scan. Both
ShMOLLI and MOLLI T1 sequences were performed using
previously published algorithms [16,17]. For ShMOLLI, the
resulting pixel-by-pixel color T1 maps were displayed using
a customised 12 bit look up table where normal myocar-
dium was green, increasing T1 red and decreasing T1 blue.
The color-map was immediately available after data ac-
quisition. A region of interest (ROI) was drawn directly on
each T1 map using ARGUS software (Siemens, Erlangen,
Germany) and T1 values averaged between all pixels. T1
was measured in the basal to mid septum in the short axis
plane taking care to avoid the blood/myocardial boundary.
A second ROI was drawn in basal and mid infero-lateral
wall and later compared with LGE images. For test-retest
reproducibility study, this process was done for both
ShMOLLI and MOLLI sequences.
The analyses were carried out by two blinded ob-
servers (SP and DS): SP analyzed the same ShMOLLI and
MOLLI mid short axis picture twice for intra-observer re-
producibility, DS analysed all studies (including re-test)
once, making intra-observer, inter-observer and inter-
study data available. For these analyses, all scans were
anonymized, i.e. scan 1 and 2 split up.
All patients enrolled underwent ECG and echocardio-
graphic examination within two days of the CMR study.
ECG analysis comprised the assessment of cardiac rhythm
and axis, PR interval, QRS interval, indices of LVH includ-
ing RE score [18]. Echocardiography was performed using
commercially available systems (Vivid 7 or 9, GE Health-
care). A routine study was performed, according to stan-
dard protocols of the European Society of Cardiology,
including evaluation of diastolic function with conven-
tional Doppler based measurements (trans-mitral E/A
ratio, E wave deceleration time, pattern of pulmonary vein
flow); Tissue Doppler was performed to assess S’ and E’
mitral annular velocities at the septal and lateral corners,
with the measurements being averaged. The E/E’ ratio was
Table 1 BSA-normalized LVmass cut-offs age and gender stratified for LV-hypertrophy definition
20–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years
Females LVmass/BSA (g/m2) 62(47–77) 62(47–77) 63(48–77) 63(48–78) 63(48–78) 63(49–78)
Males LVmass/BSA (g/m2) 76(59–93) 75(59–92) 75(58–91) 74(57–91) 73(57–90) 73(56–89)
Adapted from Maceira et. al.
BSA: body surface area; LV: left ventricle.
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tine grey scale two-dimensional cine loops from three
consecutive beats were obtained from standard apical and
short axis views. Systolic 2D strain was calculated by real-
time tracking of natural acoustic markers during consecu-
tive frames by 2D strain software as previously described
[19]. All data was prospectively and blindly analysed for
global and infero-lateral longitudinal, circumferential and
radial strain.
Exclusion criteria for this study were usual contraindi-
cations to perform a CMR scan. Patients with eGFR
<30 ml/min were not administered gadolinium contrast
and patients with sub-optimal acoustic window or frame
rates were excluded from the speckle tracking strain
analysis.
Data analysis and statistics
Data were analysed with JMP® 8.0.2 software. Data follow-
ing a parametric distribution (Shapiro Wilk test p > 0.05)
was described using mean ± standard deviation. Non-
parametric data was described using median and inter-
quartile range. Count and percent were used to describe
categorical data. The difference between groups was com-
pared with either the Student t test (parametric) or the
Mann Whitney U test (non parametric) and Fisher’s exact
test for categorical data Correlations between parameters
are described either with Pearson R or with Spearman
ρ (rho), depending on their distribution. Inter-study, intra-
observer and inter-observer reproducibility of native T1
measurements was assessed by calculating the Intraclass
Correlation Coefficient (ICC) with Pearson correlation and
Bland Altman plots and the coefficient of variance (COV).
A p value <0.05 was considered statistically significant.Table 2 Baseline characteristics of the study population
Parameter FD global cohort (n = 63) FD LVH negative
Age (years) 48 ± 15 39 ± 16
Sex (M/F) 29/34 6/19
BSA (m2) 1.8[1.7, 2] 1.7[1.6,1.8]
LVH (%) 38(60) 0
ERT (%) 49(78) 14(56)
Any LGE (%) 30(54) 4(17)
LGE infero-lateral wall 29(51) 4(17)
Data are expressed as n(percentage) or mean ± standard deviation.
BSA: body surface area; LVH: left ventricular hypertrophy; ERT: enzymatic replacingResults
Who is in study: baseline characteristics
Sixty-three patients were included in the study. Of the 63
patients, 44 had previously been studied from a cohort
previously published [13]. Two of these were rescanned
with reproducibility and 19 new patients were added. The
present study added ECG and echocardiographic data for
clinical correlations.
Baseline characteristics of Fabry disease and healthy vol-
unteers are showed in Table 2. Seven patients were not ad-
ministered gadolinium contrast, either due to severe renal
impairment (estimated glomerular filtration rate, eGFR,
<30 ml/min, n = 5), or patient refusal (n = 2). Twelve
patients with sub-optimal acoustic window or frame rates
were excluded from speckle tracking strain analysis.
Age and gender reference ranges for T1
Native T1 is known to be influenced by gender and (to a
much lesser extent) age [12,20]. For comparison with
healthy controls therefore, on the same scanner/set-up,
normal ShMOLLI ranges (and therefore limits of normal)
were constructed for Fabry disease male and female co-
horts. Age and gender matched comparator groups se-
lected from a pool of 63 healthy volunteer scans were used
to identify what the normal and low native T1 is for male
and female population. Using these, the native T1 ranges
were (mean, SD, lower limit of normal): mean 968 ± 32 ms,
lower limit 904 ms in total population; mean 956 ± 27 ms,
lower limit 902 ms in male subgroup and mean 978 ±
34 ms, lower limit 910 ms in female subgroup.
Mean septal T1 in Fabry disease males (n = 29) was lower
than in females (n = 34), (841 ± 46 ms vs 901 ± 45 ms,
p <0,0001).(n = 25) FD LVH positive (n = 38) Healthy volunteers (n = 63)
54 ± 11 47 ± 16
23/15 29/34





therapy; LGE: late gadolinium enhancement.
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vided into two groups (based on the presence or absence
of LVH) are shown in Table 3. ECG and Echocardiographic
characteristics of Fabry disease subjects are shown in
Table 4. The QRS width was directly correlated with left
ventricular mass, Pearson R = 0.72, p < 0.0001. An example
of T1 mapping in Fabry disease individuals is in Figure 1.
T1 in Fabry disease: LVH positive vs LVH negative
Septal T1 in Fabry disease subjects LVH positive (n = 38)
was lower than in LVH negative (n = 25) and healthy vol-
unteers (n = 63), (853 ± 50 ms vs 904 ± 46 ms vs 968 ±
32 ms respectively, p < 0.0001) (Figure 2); there was a
weak negative correlation between native T1 and hyper-
trophy (expressed as left ventricular mass), Pearson
R = −0.26, p = 0.03. Of the LVH positive Fabry disease
subjects, 34 (89%) had low T1 (<902 ms for males,
<910 ms for females). Of the Fabry disease LVH negative
subjects, 12 (48%) had low T1.
T1 in LVH positive population
Thirty-four of thirty-eight patients (89%) of LVH positive
patient had low septal T1, ranging from 771 ms to
908 ms. The 4 Fabry disease subjects with ‘normal’ septal
T1 were females, 3 of them with mild LVH or apical
prevalent LVH and 2 of them with basal infero-lateral
LGE and >3 years of ERT (minimum 5, maximum
12 years). One subject, 44 years, had severe concentric
hypertrophy, T1 = 978 ms, 2 years of ERT and extensiveTable 3 CMR characteristics of Fabry disease patients divided
Healthy volunteers (n = 63) FD
LV Mass i (g/m2) 66 ± 14
Max wall thickness (mm)
LVEDVi (ml/m2) 72 ± 13
LVESVi (ml/m2) 24 ± 7
LVEF (%) 67 ± 5





Average septal T1 (ms)* 968 ± 32
Average infero-lateral T1 (ms)*
Average infero-lateral T1 (ms)*
LGE yes
LGE no
Data are expressed as n (percentage) or mean ± standard deviation.
*native T1 measured by ShMOLLI sequences.
†p value between LVH negative and LVH positive groups.
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volu
RV: right ventricle.LGE. For this small group (n = 4), standard and ad-
vanced echo and CMR parameters were the same as the
low T1 LVH positive group. The ECG (QRS) was nar-
rower in this group however (94 ± 7 ms vs 117 ± 23 ms,
p < 0.01).
Regionally, native T1 in the infero-lateral wall tracked
the presence (n = 25) or absence (n = 9) of LGE in this
area (LGE+ native T1 919 ± 63 ms vs LGE- native T1
848 ± 32 ms, p < 0.01).T1 in LVH negative population
Of the LVH negative subjects who were administered
contrast (n = 23), 4 (17%) had LGE, always in the infero-
lateral wall. This was associated with normal mean T1 in
the infero-lateral segment as compared with lower T1 in
subjects without LGE (954 ± 15 ms vs 888 ± 41 ms,
p < 0.0001). We found no correlation between mean septal
T1 and LGE. Mean septal T1 was comparable in patients
with and without LGE (902 ± 49 ms vs 908 ± 46 ms, p 0.8)
Fabry disease patients without LVH had a mean septal
T1 at the lower limit of normal range (904 ± 46 ms), ran-
ging from 818 ms to 979 ms (Figure 2).
Based on the ShMOLLI mean value of 956 ± 27 ms for
males and 978 ± 34 ms for females, we divided our popula-
tion into four groups, according to presence/absence of
LVH and low/normal native septal T1, (−2SD below
healthy mean: 902 ms cut-point for males and 910 ms cut-
point for females). Group 1: LVH negative-T1N, n = 13;into LVH positive/LVH negative and Healthy volunteers
LVH negative (n = 25) FD LVH positive (n = 38) p-value†
72 ± 13 132 ± 46 <0.01
8 ± 2 16 ± 4 <0.01
70 ± 15 67 ± 16 0.30
17 ± 6 16 ± 6 0.10
74 ± 6 78 ± 7 0.05





904 ± 46 853 ± 50 <0.01
894 ± 65 903 ± 45 0.27
954 ± 15 919 ± 63 0.01
888 ± 41 848 ± 32 <0.01
me; LGE: late gadolinium enhancement; LVEF: left ventricular ejection fraction,
Table 4 ECG and Echocardiographic characteristics of Fabry disease patients divided into LVH negative and LVH
positive
LVH negative (n = 25) LVH positive (n = 38) p-value
PR interval (ms) 149 ± 32 158 ± 29 0.25
QRS interval (ms) 92 [85, 100] 108 [96, 130] <0.01
Axis (degree) 60 [47, 74] 38 [−12, 63] <0.01
TWI 3 (12) 30(79) <0.01
Sokolow (Sv1 + RV5/6) (mm) 32 ± 9 37 ± 18 0.06
RE score≥4 3 (12) 32 (84) <0.01
E/E’ 6 [5,8] 10 [8,13] <0.01
Systolic velocity Doppler TDI (m/s) 0.09 ± 0.02 0.06 ± 0.01 <0.01
Left atrial volume (ml) 60 ± 18 91 ± 28 <0.01
Global longitudinal strain (%) −20 ± 3 −13 ± 4 <0.01
Infero-lateral longitudinal strain (%) −21 ± 3 −13 ± 4 <0.01
Global basal radial strain (%) 38 ± 19 34 ± 12 0.22
Infero-lateral basal radial strain (%) 44 ± 14 34 ± 15 0.02
Global basal circumferential strain (%) −18 ± 4 −15 ± 5 0.03
Infero-lateral basal circumf strain (%) −13 ± 5 −10 ± 8 0.05
TAPSE (mm) 23 ± 4 20 ± 3 <0.01
Data are expressed as n (percentage) or mean ± standard deviation or median [interquartile range].
TWI: T wave inversion; TDI: Tissue Doppler Imaging; TAPSE: tricuspid annular plane systolic excursion.
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positive-T1↓, n = 34; Group 4: LVH positive-T1N, n = 4.
Significance of T1 lowering in LVH negative Fabry disease
subjects.
There were 25 Fabry disease patients without LVH: 13
with normal T1 and 12 with low T1. Comparing theseFigure 1 Native T1 mapping in Fabry disease using ShMOLLI at 1.5 T
clear myocardial T1 reduction – the myocardium is blue. Bottom left: Typic
and the basal infero-lateral wall has T1 elevation with a normal (pseudonor
has a normal T1.groups, the ECG was the same between groups. Standard
CMR and Echo parameters for heart size and function
were the same, but advanced echocardiography tech-
niques revealed differences in systolic and diastolic func-
tion with slightly lower global longitudinal speckle
tracking strain, and reduced diastolic function based on E/
E’ in LVH negative-T1↓ subjects (Figure 5). This also. Top left: normal. Top right: a Fabry disease subject without LVH but
al T1 when LVH present: the myocardial T1 is lower than without LVH
mal?) surrounding area. Bottom right: rarely (4 patients), Fabry disease
Figure 2 Mean septal T1 in LVH negative patients (n = 25), LVH positive patients (n = 38) and healthy volunteers (n = 63). Red solid line
indicates -2SD below the mean native T1 of females healthy volunteers. Blue solid line indicates -2SD below the mean native T1 of males
healthy volunteers.
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−0.41, p 0.07; T1 vs E/E’ Spearman rho = −0.51, p = 0.01),
Table 5 and Figure 3. Supporting diastolic impairment, left
atrial size was bigger in LVH negative-T1↓ subjects than
in LVH negative-T1N.
Considering the cut off value of 902 ms for males
and 910 ms for females, T1 had 48% sensitivity (i.e. halfTable 5 Echocardiographic, CMR, ECG characteristics of LVH n
or low T1 (LVH negative-T1↓)
LVH negative-T1N, (n
E/E’ 5[5,6]
Global longitudinal strain (%) −22 ± 2
Infero-lateral longitudinal strain (%) −23 ± 3
Global basal radial strain (%) 37 ± 24
Infero-lateral basal radial strain (%) 45 ± 15
Global basal circumferential strain (%) −18 ± 5
Infero-lateral basal circumf strain (%) −15 ± 6
TAPSE (mm) 23 ± 4
Systolic velocity Doppler TDI (m/s) 0.09 ± 0.02
PR interval (ms) 148 ± 22
QRS interval (ms) 93 ± 9
TWI 1(8)
RE score≥4 2(15)
Left atrial area i (cm2/m2)* 11 ± 2
LVEDVi (ml/m2)* 67 ± 7
LV mass i (g/m2)* 69 ± 10
Data are expressed as n(percentage) or mean ± standard deviation or median [inter
TDI: Tissue Doppler Imaging; TAPSE: tricuspid annular plane systolic excursion; TWI:
*by CMR.did not have low T1), but 99% specificity in distinguish-
ing between Fabry disease LVH negative subjects and
healthy volunteers (Receiver operating characteristic
AUC 0.73).
ShMOLLI and MOLLI sequences derived exactly the
same results but with, as previously described, a se-
quence design related 60 ms offset (MOLLI higher) [21].egative individuals with normal (LVH negative-T1N)
= 13) LVH negative-T1↓, (n = 12) p-value
7[6,8] 0.03
−18 ± 2 <0.01
−20 ± 4 0.01
39 ± 13 0.36
42 ± 15 0.70
−18 ± 4 0.99
−12 ± 3 0.12
23 ± 4 0.96
0.08 ± 0.02 0.36
150 ± 42 0.45
95 ± 11 0.26
2(17) 0.56
1(8) 0.46
13 ± 2 <0.01
72 ± 19 0.22
76 ± 16 0.19
quartile range].
T wave inversion; LVEDV: left ventricular end-diastolic volume;
Figure 3 Systolic and diastolic function in LVH negative Fabry disease patients. Global longitudinal speckle tracking strain of LVH negative-
T1↓ subjects vs LVH negative-T1N subjects (left); E/E’ of LVH negative-T1↓ subjects vs LVH negative-T1N subjects (right).
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T1 mapping was highly reproducible regardless of meth-
odology used (Table 6): inter-study reproducibility for
ShMOLLI sequences showed an intraclass correlation co-
efficients (ICC) of 0.992 and relative difference between
the means of −0.3% (95%CI −4.6% to 4.0%) (Figure 4).
Intra-observer and inter-observer reproducibility were
similarly very good with relative difference between the
means of −0.3% (95% CI −4.6% to 4.0%) and −0.8% (95%Figure 4 Reproducibility of ShMOLLI sequences. ShMOLLI inter-study corCI −3.5% to 5.0%) respectively. ShMOLLI and MOLLI se-
quences showed the same reproducibility.
Discussion
As previously described, decreased native myocardial T1
is highly prevalent in Fabry disease patients with LVH.
We show in addition that in subjects without LVH,
reduced myocardial T1 has a 50% prevalence and is as-
sociated with echocardiographic parameters of cardiacrelation (upper pannel) and Bland Altman analysis (lower pannel).
Table 6 ShMOLLI and MOLLI T1 reproducibility
Inter-study ICC (COV%) Intra-observer ICC (COV%) Inter-observer ICC (COV%)
ShMOLLI T1 0.992(0.8%) 0.976(1.5%) 0.973(1.4%)
MOLLI T1 0.978(1.5%) 0.978(1.2%) 0.982(1.1%)
ICC: intraclass correlation coefficient; COV: coefficient of variance.
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cardiac disease. As a candidate biomarker, native myo-
cardial T1 in Fabry disease is useful both in established
and early disease, and with both MOLLI and ShMOLLI
approaches.
There are many current clinical challenges in Fabry
disease. For example, the diagnosis is often missed and
there is uncertainty as when to begin ERT and also how
to monitor its effects. CMR derived myocardial T1 map-
ping has previously been shown to have very high sensi-
tivity and specificity to discriminate Fabry disease patients
with LVH [12,13]. Low T1 in Fabry disease is likely a con-
sequence of the progressive sphingolipid storage in the
myocardium. We suspect that it may be the specific stor-
age pattern of lipid in Fabry disease i.e. the lamellar bodies
with water restricted between layers, reminiscent of the
myelin sheath rather than just the presence of fat [13].
We have previously proposed 4 phases of myocardial
Fabry disease (with these data adding myocardial dys-
function to phase 2): phase 1: normal; phase 2: low T1,
early myocardial dysfunction; phase 3, LVH low T1 and
phase 4: ‘pseudonormalisation’ of T1, fibrosis and heart
failure. This study shows that low T1 is not quite ubiqui-
tous in LVH positive patients with 4 patients not having
a reduced septal T1. Whilst one of these may have been
in a progressive disease phase 4, where scarring is caus-
ing “pseudonormalisation” of T1, the other 3 were fe-
male heterozygotes with early disease or with an apical
HCM like LVH pattern and were on ERT. One tantalis-
ing explanation is that ERT in early disease may normal-
ise T1. The efficacy of ERT appears to decrease with the
progression of the disease and may be unsuccessful
when marked fibrosis has been established [6,22]. If stor-
age can be removed before the myocyte and myofibro-
blast activate and induce hypertrophy and fibrosis,
cardiac disease could be avoided. The link of low T1 to
early dysfunction may indicate the early stages of such
activation. These 50% of LVH negative individuals with a
low T1 could therefore be a target for early ERT. The re-
producibility data for native T1 has been documented in
other diseases [10,20,23,24] and here appears to be a re-
liable marker in Fabry disease, at least when performed
on the same magnet. There are ongoing research pro-
grams working on standardization between magnets.
This reproducibility is not found in advanced echocar-
diographic parameters where increased sensitivity be-
tween groups (here lower global longitudinal strain and
a worse E/E’ ratio) has not yet been matched with robustinter-subject reproducibility and the ability to guide ther-
apy in an individual [19,25-28]. This provides three poten-
tial advantages: first, a potentially clear risk stratification
and therapy targeting method; secondly, a way of clinically
monitoring therapy; and thirdly, a surrogate endpoint for
drug development, dose ranging and clinical trials. An in-
tegrated imaging approach including both cardiac mag-
netic resonance and echocardiographic parameters might
be optimal for the management of these patients.
Limitations
CMR, ECG and echocardiographic findings were not com-
pared to the gold standard of cardiac biopsy, or candidate
measures of myocardial storage such as CMR derived spec-
troscopy. The reproducibility work is single centre, single
magnet and therefore further work will be required to as-
sess these variables in scanners from different vendors and
at 3 Tesla field strength. A potential limitation of the family
of T1 mapping methods used in this paper is the depend-
ence of the T1 values on other physical parameters such as
T2 and magnetization transfer (MT), which have been
shown to affect apparent T1 values [29].
Furthermore, because of small numbers especially in LVH
negative group, separate analysis by gender or prior ERT use
were prevented. Future work will need to be larger, multi-
centre and look at both disease progression and impact of
therapy. Lastly, we didn’t measure extracellular volume
(ECV) in our population. Because ECV is a ratio, ECV
might be more comparable across platforms and sequences.
However, we didn’t measure ECV based on previous data
from our center, showing ECV didn’t raise in AFD patients.
Conclusions
Native T1 mapping is highly reproducible in Fabry dis-
ease using either ShMOLLI or MOLLI sequences. In
Fabry disease LVH negative individuals, low native T1
tracks early myocardial dysfunction and appears to be a
promising tool to detect early cardiac involvement in
Fabry disease individuals.
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